Holista Colltech Limited AI Stock Analysis
Want to see AU:HCT full AI Analyst Report?
Holista Colltech Limited (HCT) AI Stock Analysis
Holista Colltech Limited
(ASX:HCT)
The score is weighed down primarily by weak financial performance (revenue contraction, deeper losses, and sustained negative free cash flow indicating funding risk). Technical indicators also point to a bearish trend with strong downside momentum. Valuation provides limited support due to negative earnings and no dividend yield.
Holista Colltech Limited (HCT) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 12.51M
- Dividend Yield
- ―
- Average Volume (3M)
- 29.23K
- Price to Earnings (P/E)
- -3.9
- Beta (1Y)
- 0.48
- Revenue Growth
- 0.72%
- EPS Growth
- -486.96%
- Country
- Australia
- Employees
- 3
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Biotechnology
Holista Colltech Limited Business Overview & Revenue Model
Company Description
Holista CollTech Limited is a biotechnology firm with operations spanning Australia, Malaysia, and the United States. Its business activities are organized into four key divisions: Supplements, Ovine Collagen, Infection Control Solutions, and Food In...
How the Company Makes Money
HCT’s core revenue model is centered on monetizing proprietary or in-house developed health and nutraceutical products and ingredients. The company makes money primarily through (1) sales of finished products (e.g., branded or private-label nutraceut...
Holista Colltech Limited Financial Statement Overview
Summary
Financials indicate significant strain: revenue contracted sharply in the latest period, profitability worsened into a deeper net loss, and cash burn remains persistent with negative operating and free cash flow. While equity returned to positive in 2025, leverage remains high relative to equity, leaving elevated funding and execution risk.
Income Statement
24NegativeBalance Sheet
38NegativeCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.87M | 5.76M | 5.60M | 5.95M | 8.24M | 8.02M |
| Gross Profit | 1.16M | 770.25K | 87.03K | 370.06K | 4.24M | 1.31M |
| EBITDA | -489.16K | -788.46K | 304.37K | -4.52M | -1.02M | -957.40K |
| Net Income | -3.22M | -948.92K | -84.21K | -4.81M | -1.45M | -1.26M |
Balance Sheet | ||||||
| Total Assets | 3.72M | 5.87M | 3.34M | 3.35M | 5.52M | 6.93M |
| Cash, Cash Equivalents and Short-Term Investments | 564.56K | 2.16M | 21.72K | 59.77K | 117.53K | 1.21M |
| Total Debt | 1.32M | 1.59M | 1.77M | 1.57M | 1.22M | 890.32K |
| Total Liabilities | 6.70M | 6.29M | 6.71M | 6.74M | 3.96M | 3.95M |
| Stockholders Equity | -1.48M | 1.12M | -1.73M | -1.97M | 2.83M | 4.10M |
Cash Flow | ||||||
| Free Cash Flow | -1.45M | -1.52M | -1.02M | -411.67K | -1.19M | -1.72M |
| Operating Cash Flow | -1.28M | -1.35M | -1.01M | -407.12K | -1.11M | -1.68M |
| Investing Cash Flow | -29.88K | -176.36K | 692.12K | -46.70K | -105.69K | 50.35K |
| Financing Cash Flow | 1.86M | 3.65M | 143.75K | 418.42K | 120.85K | 109.49K |
Holista Colltech Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HCT, the sentiment is Negative. The current price of 0.03 is above the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.04, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 22.18 is Positive, neither overbought nor oversold. The STOCH value of -11.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HCT.
Holista Colltech Limited Peers Comparison
Overall Rating
AU:BLS84Outperform
AU:CLV76Outperform
AU:NOU49Neutral
AU:BUB48Neutral
AU:NGS46Neutral
AU:HCT39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 84Outperform | AUD 195.94M | 23.09 | 56.29% | ― | 160.87% | 188.14% | |
| 76Outperform | AUD 200.40M | 18.37 | 13.83% | 1.96% | 13.26% | 49.05% | |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| 49Neutral | AUD 34.64M | -0.53 | 13.40% | ― | 8.82% | 55.22% | |
| 48Neutral | AUD 66.24M | -13.65 | -11.08% | ― | 9.08% | -183.87% | |
| 46Neutral | AUD 18.32M | -0.01 | -130.72% | ― | -33.05% | 94.22% | |
| 39Underperform | AUD 12.51M | -3.91 | 1795.70% | ― | 0.72% | -486.96% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:HCT | Holista Colltech Limited | 0.03 | -0.05 | -60.00% | |
| AU:NOU | Noumi Limited | 0.13 | 0.01 | 4.17% | |
| AU:BLS | Bioxyne Limited | 0.83 | 0.46 | 124.32% | |
| AU:BUB | Bubs Australia Ltd. | 0.07 | -0.07 | -49.29% | |
| AU:NGS | Nutritional Growth Solutions Ltd. | 0.02 | -0.00 | -17.39% | |
| AU:CLV | Clover Corporation Limited | 1.15 | 0.35 | 43.57% |
Holista Colltech Limited Corporate Events
Holista Colltech Lifts Margins, Books One-Off Loss as ProImmune Dispute Settled
Holista Colltech reported a 3.6% rise in group revenue to $2.99 million for the half year to June 2026, with gross margin improving to 44.3% on a better sales mix and cost control. The dietary supplements division drove performance with 12.2% sales g...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 20, 2026
